Lightcalls.com
 

Brian Michael Bendis is single of t...

Brian Michael Bendis is single of the most prolific writers in comicdom today. He’s penn a number of critically acclaimed crime and espionage graphic novels, the superheroic police series Powers, and the detective series Alias (no relation to the TV show) He’s also revitalized a number of Marvel characters, including Spider-Man in the Ultimate Spider-Man series, which is the basis for Activision’s modern game.

CGW: Who would you say is your favorite character you’ve written about?

Bendis: Wow That’s like Sophie’s choice. I couldn’t possibly single out But my all-time faves were Spidey and Daredevil, for a like reason I am blessed.

CGW: Is there a comic-book character you’ve wanted a chance to bring back if it be not that haven’t yet?

Bendis: Yeah, there’s a prolonged laundry list. The new the same is Ultimate Moon Knight, [which features month Knight], who is showing up in Ultimate Spider-Man. That was a big the same for us, to kind of point out to Moon Knight in a recently made known light and, you know, indicate him off a little bit.



CGW: Can you talk about the proces of working onward the story for the Ultimate Spider-Man game? by what mode does it feel going from a comic volume to an interactive medium?

Bendis: It was like college edifice [i]or[/i] building for me…and it was just a great time for me as a writer, because you have this certain thing [with] a comic part no matter what you do. It’s 22 pages and there’s a format that you go in the rear [i]or[/i] in the wake of Then all of a unlooked for here’s this challenge: to write the same characters in an entirely different medium, an entirely different format, with the reader being the director, if you know what I mean. thus really, not only was it exciting to write that, it actually altered the way I was approaching the comic as well.

CGW: And we understand that the story you’re writing carries through directly from the comics.

Bendis: Yeah, it’s Ultimate continuity, top to bottom. And it’s just another Ultimate Spider-Man story, further this story [answers] a fortune of the questions people continue asking us online. What happened to Venom? substance like that. And the game is the no other than place you’ll see it. Unfortunately, I’m not allowed to talk any more about that for now!

Copyright ?© 2005 Ziff Davis Media Inc. All Rights Reserv Originally appearing in Computer Gaming World.



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.